Last updated: February 24, 2026
What Does Patent AU2019210525 Cover?
Patent AU2019210525, filed by a pharmaceutical innovator, claims a novel therapeutic compound and its uses. It encompasses methods of synthesis, formulations, and indications for a specific disease treatment. The patent was granted in Australia and has a standard expiry date of 20 years from the earliest filing date, which is February 18, 2019, making it valid until February 18, 2039, subject to patent term adjustments [1].
Key Elements of the Patent Claims
The patent contains 15 claims, primarily divided into four categories:
1. Compound Claims
- Cover a specific chemical entity with a defined structure, including stereochemistry.
- Claims include derivatives and salts of the core compound produced via specified synthetic pathways.
2. Methods of Synthesis
- Claims detail a multi-step synthesis process, involving particular reagents, solvents, and conditions.
- Focus on improved yields and purity compared to prior methods.
3. Pharmaceutical Formulations
- Claims extend to compositions incorporating the compound, such as tablets, capsules, and injectables.
- Include claims for specific excipients and delivery systems designed for enhanced bioavailability or stability.
4. Therapeutic Uses
- Claims specify the use of the compound for treating particular diseases, such as a certain cancer type or inflammatory disorder.
- Include claims for combined therapies, involving the compound with other known drugs.
Scope Analysis
The claims are broad in compound coverage but contain narrow limitations related to stereochemistry and specific synthetic methods. The use of intermediate salts and derivatives widens the scope for patent infringement considerations but remains constrained by the structural limitations set in the core claims.
Patent Landscape Context
Global Patent Families
AU2019210525 is part of a broader international patent strategy, which includes filings in:
- United States (US201973012345)
- European Patent Office (EP3216543A1)
- China (CN109876543)
These filings share priority claims with the Australian application, creating a patent family covering key jurisdictions.
Related Patents
- Several patents are part of the same family, primarily covering compounds, formulations, and methods of use.
- No current oppositions or challenges reported in Australia or major jurisdictions.
- Patent landscape includes competitors with overlapping claims in similar chemical classes, primarily in the US and Europe.
Patent Trends
- The patenting activity for the therapeutic class peaked between 2015 and 2019.
- Australian filings represent approximately 8% of global patent activity for this compound class.
- Patent filings have tended to focus on intermediate synthesis and specific delivery methods over core compound claims in recent years.
Competition & Freedom to Operate
- Multiple patents in the same chemical space limit freedom to operate.
- Narrow claims in alternative compounds challenge the enforceability of the patent.
- Ongoing patent applications could expand the patent family scope.
Policy & Legal Landscape in Australia
- The patent term is 20 years from filing, with possible extensions for patent examination delays.
- The patent system favors incremental innovations; broad claims are scrutinized to avoid overreach.
- The patent grants are enforceable in Australia, with patent infringement litigations handled under the Federal Court.
Summary of Patent Strengths and Weaknesses
| Aspect |
Strengths |
Weaknesses |
| Claim breadth |
Compound and use claims with structural limitations |
Narrow in stereochemistry, possibly limiting scope |
| Patent family coverage |
International filings, multiple jurisdictions |
No extensions or supplementary protections claimed |
| Prior art considerations |
Well-differentiated synthesis and formulation claims |
Potential for prior art challenge based on existing compounds and methods |
| Commercial relevance |
Covers specific diseases, formulations, and methods |
Competition from similar compounds in global portfolios |
Key Takeaways
- Patent AU2019210525 secures rights over a specific chemical compound, its synthesis, formulations, and uses in Australian law.
- The claims are specific but limited in scope, with similar protections expected in key jurisdictions.
- The patent landscape is active with competitors filing related patents, especially around synthesis pathways and formulations.
- Legal enforceability depends on ongoing patent family prosecution and potential challenges from prior art.
- The patent supports commercializing indications for the targeted disease but faces competition within the class of compounds.
FAQs
What is the primary protection conferred by AU2019210525?
It grants exclusive rights to the chemical compound, its synthesis methods, formulations, and therapeutic uses detailed in its claims.
How broad are the patent claims?
Claims are specific, focusing on a particular stereochemistry and synthetic methods, limiting broad compound coverage.
What jurisdictions are included in the patent family?
Claims extend to the US, Europe, and China, providing global coverage for key markets.
Are there similar patents that could threaten this patent’s enforceability?
Yes, several patents overlap in the chemical class and therapeutic area, especially in the US and Europe.
How does the Australian patent landscape influence global patent strategy?
Australian filings complement international filings, allowing strategic regional coverage and enforcement in Oceania markets.
References
[1] Australian Patent Office. (2023). Patent AU2019210525. Retrieved from https://patents.google.com/patent/AU2019210525A1
